Rupa Narayan, MD
Hematology & Oncology · Boston, MANPI 1881840056
Payments from drug & device makers
Across 42 payments — averaging $12,968 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$420K
- E.r. Squibb & Sons, L.L.C.$123K
- Novartis$2K
- AbbVie$25
- Pharmacyclics LLC, An Abbvie Company$17
Across 3 payments — averaging $338.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1K
What the payments were for
- Food & beverage$42100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 36 | $419,920 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122,701 |
| Novartis | 3 | $1,985 |
| AbbVie | 1 | $25 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
How this compares
$544,647 in reported general payments places this provider in the 75th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IdhifaEnasidenib Mesylate | 23 | $766,563 |
| InqoviDecitabine/Cedazuridine | 16 | $127,786 |
| Acyclovir | 32 | $1,152 |
| Hydroxyurea | 23 | $669 |
| Allopurinol | 33 | $217 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Boston
- Matthew DavidsBoston$58.6M
- Nadine TungBoston$32.4M
- Jorge CastilloBoston$31.2M
- Daniel DeangeloBoston$28.5M
- Sara TolaneyBoston$20.3M
- Paul RichardsonBoston$17.2M
- Amir FathiBoston$14.8M
- Jacqueline GarciaBoston$13.6M
- John KorethBoston$12.8M
- David ReardonBoston$12M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.